Gland Pharma Ltd Q4 FY26 Results

Summary

Gland Pharma Limited announced record financial results for the fourth quarter and full fiscal year ended March 31, 2026. For Q4 FY26, revenue from operations grew by 22% year-on-year to ₹17,428 million, while adjusted Profit After Tax (PAT) saw a significant 97% increase to ₹3,667 million, with an adjusted PAT margin of 21%. The full fiscal year FY26 performance was equally strong, with consolidated revenue up 14% to ₹64,307 million and an adjusted EBITDA margin of 26%. Executive Chairman Mr. Srinivas Sadu highlighted robust growth in the CDMO segment, new product launches, and cost-efficiency initiatives as key drivers, expressing confidence in sustaining this momentum through a pipeline of complex products and expanding CDMO partnerships.

Key Highlights

1. 1

   Gland Pharma reported a record fourth-quarter revenue from operations of ₹17,428 million, marking a 22% increase year-on-year.

2. 2

   Adjusted Profit After Tax (PAT) for Q4 FY26 surged by 97% year-on-year to ₹3,667 million, with the adjusted PAT margin reaching 21%.

3. 3

   For the full fiscal year FY26, the company achieved consolidated revenue growth of 14% to ₹64,307 million and adjusted PAT growth of 50% to ₹10,455 million.

4. 4

   The adjusted EBITDA margin for FY26 stood at 26%, while the quarterly adjusted EBITDA margin was 30%.

5. 5

   The Contract Development and Manufacturing Organization (CDMO) business was a significant contributor, accounting for 46% of revenues and growing by 36% year-on-year in Q4 FY26.

6. 6

   The Board of Directors recommended a final dividend of ₹20 per share.